Pilot results of a web based patient decision aid for first-line treatment of relapsing-remitting multiple sclerosis patients
ECTRIMS Online Library. Lapointe E. 10/26/17; 200455; P800
Emmanuelle Lapointe
Emmanuelle Lapointe
Contributions
Abstract

Abstract: P800

Type: Poster

Abstract Category: Therapy - disease modifying - 32 Others

Background: Most patients with relapsing-remitting multiple sclerosis (RRMS) wish to be actively involved in their care (1). With the emergence of new disease-modifying therapies (DMTs), treatment decision-making is increasingly complex. Patient decision aids (PtDAs) can help match therapies with individuals' characteristics and values, potentially facilitating treatment decision-making (2).
Objective: To assess the usability and usefulness of a prototype web-based PtDA for first-line therapies in patients with RRMS.
Design: The PtDA was developed following international standards and consisted of
1) background information about RRMS and available first-line DMTs;
2) interactive questions based on 6 issues previously identified as influencing decision-making (3) were used to clarify patients' characteristics and treatment preferences;
3) a knowledge quiz and 1 page summary. Treatment naïve patients in the process of initiating a first-line DMT were recruited from the local MS clinic. After trialling the PtDA, they completed the System Usability Scale (SUS) (4) and the Preparation for Decision Making scale (5) to determine overall usability and preparation.
Results: 18 RRMS patients participated in the usability testing. For the PrepDM scale: overall, 76% of patients affirmed the PtDA “greatly” or “quite” helped their decision-making process with nearly all patients suggesting it increased their desire for involvement and awareness of the importance of their personal preferences. Perceived benefit on the understanding of each treatment option was also high (89%). Moreover, 70% felt “greatly” or “quite” better prepared to discuss treatment options with their care provider. 89% considered the information they got from the PtDA was consistent with previous discussions involving health care professionals. In terms of usability, the majority (78%) stated they would like to use the PtDA frequently and 94% found it was easy to use. The mean SUS score was 80.6 [range 50-100].
Conclusions: The results suggest our web based PtDA is promising, usable and useful in preparing and engaging RRMS patients in treatment decision-making.
1. Heesen et al. Mult Scler. 2004
2. Stacey et al. Cochrane database of systematic reviews. 2017
3. Lynd et al. Ther Adv Neurol Dis. 2016
4. Borsci et al. Cogn Process. 2009
5. Bennet et al. Patient Educ Couns. 2010
Disclosure:
Emmanuelle Lapointe has received consulting fees from Roche.
Nick Bansback and Judy A. Chiu have no disclosure.
Anthony Traboulsee: has received grant funding from the MS Society of Canada, Canadian Institute for Health Research, Roche, and Genzyme; received honoraria or travel grants from Teva Canada Innovation, Roche, Merck/EMD Serono, Genzyme, Chugai Pharmaceuticals.
Robert Carruthers is a site principal investigator for studies funded by MedImmune, Teva, and Guthy Jackson. He has received speaking fees for unbranded lectures from Biogen, Genzyme, and Teva. He has received consulting fees for Novartis, EMD Serono, and Genzyme.

Abstract: P800

Type: Poster

Abstract Category: Therapy - disease modifying - 32 Others

Background: Most patients with relapsing-remitting multiple sclerosis (RRMS) wish to be actively involved in their care (1). With the emergence of new disease-modifying therapies (DMTs), treatment decision-making is increasingly complex. Patient decision aids (PtDAs) can help match therapies with individuals' characteristics and values, potentially facilitating treatment decision-making (2).
Objective: To assess the usability and usefulness of a prototype web-based PtDA for first-line therapies in patients with RRMS.
Design: The PtDA was developed following international standards and consisted of
1) background information about RRMS and available first-line DMTs;
2) interactive questions based on 6 issues previously identified as influencing decision-making (3) were used to clarify patients' characteristics and treatment preferences;
3) a knowledge quiz and 1 page summary. Treatment naïve patients in the process of initiating a first-line DMT were recruited from the local MS clinic. After trialling the PtDA, they completed the System Usability Scale (SUS) (4) and the Preparation for Decision Making scale (5) to determine overall usability and preparation.
Results: 18 RRMS patients participated in the usability testing. For the PrepDM scale: overall, 76% of patients affirmed the PtDA “greatly” or “quite” helped their decision-making process with nearly all patients suggesting it increased their desire for involvement and awareness of the importance of their personal preferences. Perceived benefit on the understanding of each treatment option was also high (89%). Moreover, 70% felt “greatly” or “quite” better prepared to discuss treatment options with their care provider. 89% considered the information they got from the PtDA was consistent with previous discussions involving health care professionals. In terms of usability, the majority (78%) stated they would like to use the PtDA frequently and 94% found it was easy to use. The mean SUS score was 80.6 [range 50-100].
Conclusions: The results suggest our web based PtDA is promising, usable and useful in preparing and engaging RRMS patients in treatment decision-making.
1. Heesen et al. Mult Scler. 2004
2. Stacey et al. Cochrane database of systematic reviews. 2017
3. Lynd et al. Ther Adv Neurol Dis. 2016
4. Borsci et al. Cogn Process. 2009
5. Bennet et al. Patient Educ Couns. 2010
Disclosure:
Emmanuelle Lapointe has received consulting fees from Roche.
Nick Bansback and Judy A. Chiu have no disclosure.
Anthony Traboulsee: has received grant funding from the MS Society of Canada, Canadian Institute for Health Research, Roche, and Genzyme; received honoraria or travel grants from Teva Canada Innovation, Roche, Merck/EMD Serono, Genzyme, Chugai Pharmaceuticals.
Robert Carruthers is a site principal investigator for studies funded by MedImmune, Teva, and Guthy Jackson. He has received speaking fees for unbranded lectures from Biogen, Genzyme, and Teva. He has received consulting fees for Novartis, EMD Serono, and Genzyme.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies